EVIMED 60

Description

Raloxifene HCL (Raloxifene Hydrochloride) is a selective estrogen receptor modulator (SERM), similar in class to tamoxifen (Nolvadex) and clomiphene (Clomid), but with a different medical focus.

What it is

• Type: SERM (Selective Estrogen Receptor Modulator)

• Chemical form: Hydrochloride salt (HCL) for stability and oral use

• Action:

  • Blocks estrogen activity in some tissues (like breast)

  • Mimics estrogen in others (like bone)

• This selective action means it can protect bone density while reducing estrogen-driven risks in certain tissues.

Medical uses

• Approved:

  • Prevention and treatment of osteoporosis in postmenopausal women

  • Reducing risk of invasive breast cancer in certain high-risk women

• Mechanism in medicine:

  • Antagonist at estrogen receptors in breast tissue → anti-cancer effect

  • Agonist at estrogen receptors in bone → preserves bone mineral density

Bodybuilding / sports uses

• Not a top-tier PCT drug like Nolvadex or Clomid, but sometimes used:

  • Gyno treatment – blocks estrogen in breast tissue, especially useful in cases of gyno flare-ups

  • Estrogen control – mild help without significantly lowering estrogen systemically

• Less common in standard PCT protocols because it’s not as strong at stimulating LH/FSH compared to clomiphene or enclomiphene.

Dosage

• Medical: Typically 60 mg once daily

• Bodybuilding anecdotal use: 60–120 mg daily for short-term gyno treatment (not well studied in men)

Popular brand names

• Evista – most common pharmaceutical brand

• Ralista – used in some Asian markets

• Ralox – generic market name

Category for marketing

• SERM (Selective Estrogen Receptor Modulator)

• Anti-Estrogen

• Gyno Treatment / Breast Tissue Estrogen Blocker

• Hormone Modulator

Raloxifene can be used in a PCT context, but it’s not a common first choice.
It’s generally better suited for treating or preventing gynecomastia rather than fully restoring testosterone after a cycle.

Why it’s not a standard PCT base

• Raloxifene is very strong at blocking estrogen in breast tissue (better than Nolvadex for gyno reversal in some studies).

• But it’s less potent at stimulating LH/FSH compared to Clomid or Enclomiphene — which are the main hormones needed to restart testosterone production.

• This means raloxifene is often used as a specialized SERM in PCT rather than the sole SERM.

Possible PCT Use Cases

1. Standalone (rare)

• For mild cycles where testosterone suppression is minimal, some may run:

  • Raloxifene 60 mg/day for 4–6 weeks

• Goal: Moderate testosterone support + strong anti-gyno effect.

2. Combined with other SERMs (more common)

• For example:

  • Enclomiphene 25 mg/day (LH/FSH stimulation)

  • Raloxifene 60 mg/day (anti-gyno protection)
    Duration: 4–6 weeks

3. Gyno-focused protocol

• For reversing gyno (including during PCT), anecdotal bodybuilding protocol:

  • First 2–4 weeks: 120 mg/day

  • Next 2–4 weeks: 60 mg/day

  • Often combined with an aromatase inhibitor (AI) if estrogen levels are high

Key Points

• Raloxifene is more selective for breast tissue than Nolvadex or Clomid, which makes it valuable in gyno treatment.

• If the main PCT goal is restoring testosterone, Clomid or Enclomiphene is more effective — but adding raloxifene can give extra estrogen protection.

• Should be paired with bloodwork monitoring.